(P22-057-25) Nutrify Genie’s Innovative Suggestions Targeting IL-11 and GLP-1 in Aging and Chronic Disease Management

Objectives: Aging is associated with chronic diseases driven by inflammation, metabolic dysfunction, and tissue damage. Interleukin-11 (IL-11) targets inflammation, fibrosis while Glucagon-Like Peptide-1 (GLP-1) regulates metabolism indirectly associated with aging and related diseases. However, compounds targeting both simultaneously remain underexplored.

1. To utilize NutrifyGenie (NG-AI) to analyse the impact of IL-11 and GLP-1 on aging and chronic diseases.
2. To explore targets that modulate both pathways.
3. To perform molecular docking analysis to validate NG-AI suggested outputs.

Methods: NG-AI, a novel discovery platform distinct from traditional workflow tools, was used to investigate IL-11 and GLP-1's roles in aging. The platform integrated an updated, classified database with a retrieval-augmented generation framework to analyse extensive literature, uncovering knowledge gaps and intervention opportunities. Pathway analysis highlighted IL-11 and GLP-1's roles in aging-related factors like inflammation, glucose metabolism cellular senescence. Algorithms assessed data patterns to predict interactions with other molecules. Phytoactives targeting these pathways were proposed, and molecular docking validated their binding affinities for data-driven strategies for modulating aging and advancing interventions.

Results: Osthole, Pterostilbene, Anolignan A showed promising binding affinities (≈ -5.8 to -6.7 kcal/mol) for IL-11 and GLP-1, indicating potential to modulate these pathways suggesting that targeting IL-11 may reduce inflammation and fibrosis, while GLP-1 modulation can enhance metabolic regulation for managing aging-related chronic diseases.

Conclusions: The NG-AI identified IL-11 and GLP-1's roles in aging and chronic disease progression, suggesting compounds that could reduce inflammation, fibrosis, and improve metabolic regulation without the adverse effects of traditional GLP-1s. While the binding affinities to GLP-1 were moderate, one compound showed strong affinity for IL-11 and mild to moderate GLP-1 activity, offering a distinct advantage. These findings highlight promising strategies for age-related chronic diseases warranting further research.

Funding Sources: No external funding sources or financial support.